# Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)

> **NCT02011490** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 33 (actual)

## Conditions studied

- Renal Insufficiency
- Renal Impairment

## Interventions

- **DRUG:** sugammadex

## Key facts

- **NCT ID:** NCT02011490
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-11
- **Primary completion:** 2014-06-06
- **Final completion:** 2014-06-06
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02011490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02011490, "Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02011490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*